妊娠期糖尿病早期筛查:随机对照试验的荟萃分析
本荟萃分析纳入8项随机对照试验共1920名参与者,比较妊娠期糖尿病早期筛查(<20周)与常规筛查(≥20周)对妊娠结局的影响。总体而言,早期筛查与治疗未降低大于胎龄儿风险(8.1% vs 9.0%;RR 0.94,95%CI 0.73-1.22);但在首次产检普遍筛查(>80%采用HbA1c)并早期治疗的试验中,大于胎龄儿风险降低(2.3% vs 9.1%;RR 0.29,95%CI 0.09-0.90)。
要点
- 总体早期筛查与治疗未降低大于胎龄儿风险(8.1% vs 9.0%;RR 0.94,95%CI 0.73-1.22)。
- 首次产检普遍筛查(>80%用HbA1c)并早期治疗的试验中,大于胎龄儿风险降低(2.3% vs 9.1%;RR 0.29,95%CI 0.09-0.90)。
- 作者认为对所有孕妇筛查可能有益,但需未来设计良好的试验证实。
核心结论
- 总体而言,妊娠期糖尿病早期筛查与治疗未降低大于胎龄儿风险。
- 首次产检筛查所有参与者并早期治疗(多数针对HbA1c 5.7%至6.4%)的试验中,大于胎龄儿风险较常规护理降低,提示对所有孕妇筛查可能有益。
- 作者指出需未来设计良好的试验证实这些发现。
研究设计与样本
- 系统综述与随机对照试验的荟萃分析。
- 检索MEDLINE、Scopus、ClinicalTrials.gov、EMBASE、ScienceDirect、Cochrane Library对照试验中心注册库及SciELO,从建库至2021年11月。
- 纳入比较早期筛查(定义为<20周妊娠筛查)与常规筛查(定义为≥20周妊娠筛查)对妊娠结局影响的随机对照试验。
- 最终纳入8项随机临床试验,共1920名参与者,其中746名参与者为早期妊娠期糖尿病。
- 主要结局为大于胎龄儿,定义依据各试验。
主要发现
- 所有纳入试验中,早期筛查与治疗组和常规护理组的大于胎龄儿风险无显著差异(8.1% vs 9.0%;RR 0.94,95%CI 0.73-1.22)。
- 首次产检普遍筛查(>80%采用HbA1c)且筛查阳性即早期治疗的试验中,大于胎龄儿风险低于常规筛查与护理(2.3% vs 9.1%;RR 0.29,95%CI 0.09-0.90)。
局限性
- 作者指出需要未来设计良好的试验来证实这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Current evidence is conflicting on whether early screening and treatment for gestational diabetes mellitus improve pregnancy outcomes. Thus, this systematic review and meta-analysis of randomized controlled trials aimed to assess the rate of adverse pregnancy outcomes among participants with early screening and treatment for gestational diabetes mellitus vs those with routine care. DATA SOURCES: A systematic review of the literature was conducted using MEDLINE, Scopus, ClinicalTrials.gov, EMBASE, ScienceDirect, the Cochrane Library at the Central Register of Controlled Trials, and SciELO from inception to November 2021. STUDY ELIGIBILITY CRITERIA: Studies were eligible for inclusion if they described randomized controlled trials comparing early screening with routine care for gestational diabetes mellitus to assess the effects of early screening and treatment on pregnancy outcomes. METHODS: All randomized controlled trials comparing early vs standard screening of gestational diabetes mellitus assessing the effect of early screening (defined as a screening at <20 weeks of gestation) vs routine screening (defined as a screening at ≥20 weeks of gestation) on pregnancy outcomes were included. The primary outcome was defined as large for gestational age, as defined by the trial. The secondary maternal and neonatal outcomes were also evaluated. Subgroup analyses were performed on the basis of screening strategy and methods. RESULTS: After exclusion, 8 randomized clinical trials (1920 participants) of early screening and treatment vs standard care were included. There were a total of 746 participants with early gestational diabetes mellitus. The risk of large for gestational age at birth did not differ between early screening and treatment for gestational diabetes mellitus and routine care among all included trials (8.1 vs 9.0%; relative risk, 0.94; 95% confidence interval, 0.73-1.22). Trials with a protocol of universal screening of participants at their first prenatal visit (>80% screened with HbA1c) and receiving early treatment if the screening test returned positive had a lower risk of large for gestational age (2.3 vs 9.1%; relative risk, 0.29; 95% confidence interval, 0.09-0.90) than those who had routine screening and care. CONCLUSION: Overall, early screening and treatment of gestational diabetes mellitus did not reduce the risk of large for gestational age at birth. However, trials that screened all participants at their first visit and treated early, most for an HbA1c of 5.7% to 6.4%, had a reduced risk of large for gestational age at birth compared with routine care, suggesting a possible benefit of screening all pregnant patients. However, future well-designed trials are needed to confirm these findings.
引用
- McLaren RA, Ruymann KR, Ramos GA, et al. Early screening for gestational diabetes mellitus: a meta-analysis of randomized controlled trials. Am J Obstet Gynecol MFM. 2022. PMID: 36031150. doi:10.1016/j.ajogmf.2022.100737
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。